This whitepaper provides insights into why it is critical to manage, optimize and streamline a supply chain to mitigate risks, such as those brought on by the COVID-19 pandemic.
Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.
Early phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.
mRNA technology has revolutionized vaccine development. What are the chemical components that make up a typical mRNA vaccine and what are their functions? What analytical testing can be done to support this?
This year LKF Central Laboratory, which specialises in international clinical trials, celebrates its 30th anniversary. Although size and services have developed significantly since the beginning, LKF´s corporate philosophy is still the same. With its dedicated team, LKF supports clinical trials with an individual and study-oriented, flexible approach with consistent high-quality laboratory standards.
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Which connection method do most industry professionals prefer: tube welding or aseptic connectors? A recent survey revealed their preferences are almost equally split between the two. But that doesn’t mean one method might not be better for your needs.
On 13 April 2021, Evotec SE launched beLAB2122 in collaboration with Bristol-Myers Squibb company and five top-tier academic institutions. Mediated and supported by BioRN Life Science Cluster Rhine-Neckar, this $20 million BRIDGE brings together leading academic institutions in Southwestern Germany with the goal of efficiently advancing novel drug discovery projects.
The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?